Product Reports Resources Pricing Login Book a demo

Chengdu Maxvax Biotechnology

Biotech & Life Sciences · Chengdu, China · Founded 2016

CDMO for plasmid DNA, mRNA, and proteins.

Valuation $1–2.5B
Revenue $1–10M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Chengdu Maxvax Biotechnology and the history behind them.
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Talent graph

Chengdu Maxvax Biotechnology's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

14 investors on Chengdu Maxvax Biotechnology's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Korea Investment Partners
Sherpa Venture Partners
Hillhouse Capital
Series B+ 11 investors entered at this stage
Fangshizhen Capital
IDG Capital
Qianhai FOF
Xinshang Capital
GF Qianhe
Guohai Innovative CCI Capital
Sherpa Investment
Gortune Investment
China Life Private Equity Investment
Shenzhen Capital Group
Shanghai Hankang Private Equity Fund Management

Ownership

Who owns Chengdu Maxvax Biotechnology

Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.

34.7% Founders

Some investors are hidden on this public profile. “Other / undisclosed” is the 4.8% not attributed to a named shareholder. See the full cap table on Dealroom →

Global footprint

Where Chengdu Maxvax Biotechnology has talent and traffic

Workforce by country
🇨🇳 China · Chengdu HQ
Book a demo for the full country breakdown
Web traffic by country
130 monthly visits
across markets
🇺🇸 United States76.9%
Top 1 markets shown

Patent intelligence

$3M patent portfolio · 143 active families

Estimated portfolio value
$3M
0.32% of valuation · 17.1× smaller than top peer Akeso Biopharma ($59M)
143 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Chengdu Maxvax Biotechnology

An AI-synthesized read of the highest-engagement posts about Chengdu Maxvax Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Chengdu Maxvax Biotechnology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles